Abstract:Huntington disease (HD) is a fatal progressive neurodegenerative disorder for which only symptomatic treatment is available. A better understanding of the pathology, and identification of biomarkers will facilitate the development of disease-modifying treatments. HD is potentially a good model of a neurodegenerative disease for development of biomarkers because it is an autosomal-dominant disease with complete penetrance, caused by a single gene mutation, in which the neurodegenerative process can be assessed many years before onset of signs and symptoms of manifest disease. Previous MRI studies have detected abnormalities in gray and white matter starting in premanifest stages. However, the understanding of how these abnormalities are related, both in time and space, is still incomplete. In this study, we combined deep gray matter shape diffeomorphometry and white matter DTI analysis in order to provide a better mapping of pathology in the deep gray matter and subcortical white matter in premanifest HD. We used 296 MRI scans from the PREDICT-HD database. Atrophy in the deep gray matter, thalamus, hippocampus, and nucleus accumbens was analyzed by surface based morphometry, and while white matter abnormalities were analyzed in (i) regions of interest surrounding these structures, using (ii) tractography-based analysis, and using (iii) whole brain atlas-based analysis. We detected atrophy in the deep gray matter, particularly in putamen, from early premanifest stages. The atrophy was greater both in extent and effect size in cases with longer exposure to the effects of the CAG expansion mutation (as assessed by greater CAP-scores), and preceded detectible abnormalities in the white matter. Near the predicted onset of manifest HD, the MD increase was widespread, with highest indices in the deep and posterior white matter. This type of in-vivo macroscopic mapping of HD brain abnormalities can potentially indicate when and where therapeutics could be targeted to delay the onset or slow the disease progression.

Mild cognitive impairment in Huntington's disease: challenges and outlooks

Pathomechanisms of behavioral abnormalities in Huntington disease: an update

Mild cognitive impairment in amyotrophic lateral sclerosis: current view

Early alterations of motor learning and corticostriatal network activity in a Huntington's disease mouse model

Evidence for Specific Cognitive Deficits in Preclinical Huntington'S Disease

Insights into White Matter Defect in Huntington's Disease

Insights into White Matter Defect in Huntington’s Disease

Huntington disease: natural history, biomarkers and prospects for therapeutics

Resting-state Fmri Reveals Potential Neural Correlates of Impaired Cognition in Huntington's Disease.

Cognitive functions and corticostriatal circuits: insights from Huntington's disease

Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease

The pathobiology of depression in Huntington's disease: an unresolved puzzle

Huntington's Disease: Molecular Basis of Pathology and Status of Current Therapeutic Approaches.

Insights into Mechanisms, Diagnosis, and Therapeutic Implications

Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy

The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease

Executive and Mnemonic Functions in Early Huntington's Disease.

The visual cortex and visual cognition in Huntington's disease: An overview of current literature

Therapy development in Huntington disease: From current strategies to emerging opportunities

Problem solving, impulse control and planning in patients with early- and late-stage Huntington’s disease

Linking White Matter and Deep Gray Matter Alterations in Premanifest Huntington Disease.